Table 4.
Sensitivity analysis on the impact of statin use with dementia incidence and its sub-types (including statin use initiated beyond the first year of the index date).
| Dementia and subtypes | Statin non-use (ref.) | Statin use (multi-adjusted SHR, 95% CI)a |
|---|---|---|
| No. | 47,573 | 56,722 |
| All-cause dementia | 1 | 0.86 (0.82–0.90) |
| Alzheimer's disease | 1 | 0.84 (0.76–0.93) |
| Vascular dementia | 1 | 0.88 (0.78–0.99) |
| Unspecified dementia | 1 | 0.84 (0.79–0.89) |
Abbreviations: CI, confidence interval; No., number; Ref., reference; SHR, sub-distribution hazards ratio.
a
We calculated the SHR and 95% CI using the Fine Gray's test for equality of the cumulative functions between each exposure group after accounting for competing risks of all-cause mortality.